New pill for eczema tested in over 1,000 japanese patients
NCT ID NCT05387980
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tracks the safety and effectiveness of CIBINQO (abrocitinib) tablets in over 1,100 Japanese patients with atopic dermatitis (eczema) under real-world medical practice. Researchers will monitor side effects, treatment dropouts, and skin clearance over time. The goal is to see how well the drug works outside of strict clinical trial settings.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CIBINQO (abrocitinib) tablets
What this could lead to
If successful, this study could confirm that CIBINQO is a safe and effective option for controlling atopic dermatitis in Japanese patients.
What could go wrong
This is an observational study, not a controlled trial, so results may be less definitive. Side effects and treatment discontinuation are being tracked, and not all patients may benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer Local Country Office
Tokyo, Japan